Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Nexstim Receives Two New NBS System Orders in the United States | ||
| By: GlobeNewswire - 26 Mar 2020 | Back to overview list |
|
Press release, Helsinki, 26 March 2020 at 9.30 am (EET) Nexstim Receives Two New NBS System Orders in the United States Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has recently received two new NBS System orders from two large medical institutions in the United States. Nexstim NBS System uses Company’s unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in patient’s brain. NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. Nexstim NBS systems are used mainly for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery is the tumour’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. Like Nexstim’s NBT® systems, NBS Systems are used worldwide also in conducting research concerning treatment and diagnostics of several different brain diseases and disorders. Mikko Karvinen, CEO of Nexstim Plc commented: “We are happy to welcome these two medical institutions in the United States to our SmartFocus® user family where several renowned medical institutions around the world already use the NBS systems. The NBS business remains a good and steady revenue source for Nexstim, also during these unfortunate times of COVID-19, as neurosurgical operations are still in place in many hospitals.” Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information please visit www.nexstim.com Attachment |
||
|
|
||
 | Back to overview list | |